Speed of Onset and Efficacy of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in CNS Drugs
- Vol. 17 (9), 653-667
- https://doi.org/10.2165/00023210-200317090-00005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- ZolmitriptanDrugs, 1999
- Zolmitriptan, a 5‐HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose‐range finding studyEuropean Journal of Neurology, 1998
- Multiple-Attack Efficacy and Tolerability of Sumatriptan Nasal Spray in the Treatment of MigraineArchives of Family Medicine, 1998
- SumatriptanDrugs, 1998
- Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraineNeurology, 1997
- Optimizing the dose of zolmitriptan (Zomig,* 311C90) for the acute treatment of migraineNeurology, 1997
- Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)British Journal of Pharmacology, 1997
- Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine ?Pain, 1996
- Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)‐I D Receptor Agonist 311C90Headache: The Journal of Head and Face Pain, 1994
- Migraine and Drug AbsorptionClinical Pharmacokinetics, 1978